WO2021000928A1 - 激活atoh1基因的寡聚核酸分子及其应用 - Google Patents
激活atoh1基因的寡聚核酸分子及其应用 Download PDFInfo
- Publication number
- WO2021000928A1 WO2021000928A1 PCT/CN2020/100093 CN2020100093W WO2021000928A1 WO 2021000928 A1 WO2021000928 A1 WO 2021000928A1 CN 2020100093 W CN2020100093 W CN 2020100093W WO 2021000928 A1 WO2021000928 A1 WO 2021000928A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- acid molecule
- small
- strand
- atoh1
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
Abstract
Description
saRNA活性分类 | ATOH1改变幅度的log2值(倍数) | saRNA数量 | 百分比 |
高度激活 | ≥1.00(2.00)~≤2.557(5.883) | 32 | 7.9% |
轻度激活 | ≥0.14(1.10)~<1.00(2.00) | 105 | 26.1% |
无激活作用 | <0.14(1.10) | 266 | 66.0% |
总计 | 403 | 100% |
Claims (46)
- 小激活核酸分子,包含第一核酸链和第二核酸链,其中第一核酸链与ATOH1基因启动子中距转录起始位点-578至-386区域(SEQ ID NO:2)、-339至-291区域(SEQ ID NO:3)、-162至-86区域(SEQ ID NO:4)或-55至-34区域(SEQ ID NO:5)中的任一连续16-35个核苷酸具有至少75%的同源性或互补性,所述第一核酸链和所述第二核酸链能通过互补形成双链核酸结构,所述双链核酸结构能够激活/上调ATOH1基因在细胞中的表达。
- 根据权利要求1所述的小激活核酸分子,其中所述第一核酸链和所述第二核酸链存在于两条不同的核酸链上。
- 根据权利要求1所述的小激活核酸分子,其中所述第一核酸链和所述第二核酸链存在于同一条核酸链上,优选地,所述小激活核酸分子为发夹型单链核酸分子,其中所述第一核酸链和所述第二核酸链包含形成双链核酸结构的互补区域。
- 根据权利要求2所述的小激活核酸分子,其特征在于所述小激活核酸分子的至少一条链在3’端具有0至6个核苷酸的突出。
- 根据权利要求4所述的小激活核酸分子,其特征在于所述小激活核酸分子的两条链在3’端都具有0至6个核苷酸的突出,优选地具有2个或3个核苷酸的突出。
- 根据权利要求1-5任一项所述的小激活核酸分子,其特征在于所述第一核酸链和所述第二核酸链的长度分别为16至35个核苷酸。
- 根据权利要求1-6任一项所述的小激活核酸分子,其特征在于所述小激活核酸分子的一条链包括与选自SEQ ID NO:280-416中的任一核苷酸序列具有至少75%的同源性或互补性的核酸序列,或由与选自SEQ ID NO:SEQ ID NO:280-416中的任一核苷酸序列具有至少75%的同源性或互补性的核酸序列组成。
- 根据权利要求1-7所述的小激活核酸分子,其特征在于所述第一核酸链与选自SEQ ID NO:6-142的任一核苷酸序列具有至少75%的同源性,并且所述第二核酸链与选自SEQ ID NO:143-279的任一核苷酸序列具有至少75%的同源性。
- 权利要求1-8所述的小激活核酸分子,其特征在于所述第一核酸链包括选自SEQ ID NO:6-142的任一核苷酸序列或由选自SEQ ID NO:6-142的任一核苷酸序列组成,并且所述第二核酸链包括选自SEQ ID NO:143-279的任一核苷酸序列或由选自SEQ ID NO:143-279的任一核苷酸序列组成。
- 根据权利要求1-9任一项所述的小激活核酸分子,其中所述小激活核酸分子包括至少一个修饰,优选地,所述修饰为化学修饰。
- 根据权利要求10所述的小激活核酸分子,其中所述化学修饰包括或选自如下修饰中的 一种或多种:(1)对所述小激活核酸分子的核苷酸序列中连接核苷酸的磷酸二酯键的修饰;(2)对所述小激活核酸分子的核苷酸序列中的核糖的2’-OH的修饰;(3)对所述小激活核酸分子的核苷酸序列中的碱基的修饰;(4)所述小激活核酸分子的核苷酸序列中的至少一个核苷酸为锁核酸。
- 根据权利要求10所述的小激活核酸分子,其中所述化学修饰包括或选自如下修饰中的一种或多种:2’-氟代修饰、2’-氧甲基修饰、2’-氧亚乙基甲氧基修饰、2,4’-二硝基苯酚修饰、锁核酸(LNA)、2’-氨基修饰、2’-脱氧修饰、5′-溴尿嘧啶修饰、5′-碘尿嘧啶修饰、N-甲基脲嘧啶修饰、2,6-二氨基嘌呤修饰、硫代磷酸修饰和硼烷化磷酸盐修饰。
- 权利要求1-12任一项所述的小激活核酸分子,其激活/上调ATOH1基因表达至少10%。
- 编码权利要求1-9任一项所述的小激活核酸分子的核酸。
- 权利要求14所述的核酸,其中所述核酸是DNA分子。
- 包含权利要求1-13任一项所述的小激活核酸分子或权利要求14或15所述的核酸的细胞。
- 包含权利要求1-13任一项所述的小激活核酸分子、权利要求14或15所述的核酸或权利要求16所述的细胞,和任选地药学上可接受的载体的组合物。
- 权利要求17所述的组合物,其特征在于所述药学上可接受的载体包括或选自脂质体、高分子聚合物或多肽。
- 试剂盒,其包含权利要求1-13任一项所述的小激活核酸分子、权利要求14或15所述的核酸、权利要求16所述的细胞或权利要求17-18中任一项所述的组合物。
- 权利要求1-13任一项所述的小激活核酸分子、权利要求14或15所述的核酸或权利要求17-18任一项所述的组合物在制备用于在细胞中激活/上调ATOH1基因表达的制剂中的应用。
- 根据权利要求20所述的应用,其中所述小激活核酸分子被直接导入所述细胞中。
- 根据权利要求20所述的应用,其中所述小激活核酸分子是在编码该小激活核酸分子的核苷酸序列导入所述细胞后在细胞内产生的。
- 根据权利要求20-22的任一项所述的应用,其中所述细胞包括哺乳动物细胞。
- 根据权利要求20所述的应用,其中所述细胞是人类细胞。
- 根据权利要求24所述的应用,其中所述细胞存在于人体中。
- 根据权利要求25所述的应用,其中所述人体是患有与ATOH1蛋白表达不足或减少相关 的疾病或状况的患者,并且所述小激活核酸分子被施用足够的量以实现对所述疾病或状况的治疗。
- 根据权利要求26所述的应用,其中所述与ATOH1蛋白表达不足或减少相关的疾病或状况包括听力损失和肿瘤。
- 分离的ATOH1基因小激活核酸分子靶位点,其中所述靶位点包括或选自SEQ ID NO:2-5的任一条序列上的任意连续16-35个核苷酸序列。
- 根据权利要求28所述的小激活核酸分子靶位点,其中所述靶位点包括或选自SEQ ID NO:280-416中所示的任一核苷酸序列。
- 激活/上调ATOH1基因在细胞中的表达的方法,该方法包括给所述细胞施用权利要求1-13任一项所述的小激活核酸分子、权利要求14或15所述的核酸或权利要求17-18中任一项所述的组合物。
- 根据权利要求30所述的方法,其中所述小激活核酸分子被直接导入所述细胞中。
- 根据权利要求30所述的方法,其中所述小激活核酸分子是在编码所述小激活核酸分子的所述核酸导入所述细胞后在细胞内产生的。
- 根据权利要求30-32任一项所述的方法,其中所述细胞包括哺乳动物细胞。
- 根据权利要求30所述的方法,其中所述细胞是人类细胞。
- 根据权利要求34所述的方法,其中所述细胞存在于人体中。
- 根据权利要求35所述的方法,其中所述人体是患有与ATOH1蛋白表达不足或减少相关的疾病或状况的患者,并且所述小激活核酸分子被施用足够的量以实现对所述疾病或状况的治疗。
- 根据权利要求35所述的方法,其中所述与ATOH1蛋白表达不足或减少相关的疾病或状况包括听力损失和肿瘤。
- 治疗个体中与ATOH1蛋白表达不足或减少相关的疾病或状况的方法,包括给所述个体施用治疗有效量的权利要求1-13任一项所述的小激活核酸分子、权利要求14或15所述的核酸、权利要求16所述的细胞或权利要求17-18任一项所述的组合物。
- 权利要求38的方法,其中所述与ATOH1蛋白表达不足或减少相关的疾病或状况包括听力损失和肿瘤。
- 权利要求38或39所述的方法,其中所述个体是哺乳动物。
- 权利要求38所述的方法,其中所述个体是人。
- 权利要求1-13任一项所述的小激活核酸分子、权利要求14或15所述的核酸、权利要 求16所述的细胞或权利要求17-18任一项所述的组合物在制备用于治疗与ATOH1蛋白表达不足或减少相关的疾病或状况的药物中的应用。
- 权利要求42所述的应用,其中所述与ATOH1蛋白表达不足或减少相关的疾病或状况包括听力损失和肿瘤。
- 权利要求1-13任一项所述的小激活核酸分子、权利要求14或15所述的核酸、权利要求16所述的细胞或权利要求17-18任一项所述的组合物在制备用于治疗由ATOH1蛋白表达不足引发的疾病的药物中的应用,所述疾病包括听力损失。
- 权利要求43-44任一项所述的应用,其中所述个体是哺乳动物。
- 权利要求43-44任一项所述的应用,其中所述个体是人。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3145567A CA3145567A1 (en) | 2019-07-04 | 2020-07-03 | Oligomeric nucleic acid molecule activating atoh1 gene and use thereof |
EP20834537.1A EP3995578A4 (en) | 2019-07-04 | 2020-07-03 | OLIGOMERIC NUCLEIC ACID MOLECULE FOR ACTIVATING THE ATH1 GENE AND USE THEREOF |
CN202080045801.3A CN114174511A (zh) | 2019-07-04 | 2020-07-03 | 激活atoh1基因的寡聚核酸分子及其应用 |
JP2021577888A JP2022539770A (ja) | 2019-07-04 | 2020-07-03 | Atoh1遺伝子を活性化するオリゴ核酸分子及びその応用 |
US17/597,281 US20220313721A1 (en) | 2019-07-04 | 2020-07-03 | Oligomeric nucleic acid molecule activating atoh1 gene and use thereof |
AU2020298647A AU2020298647A1 (en) | 2019-07-04 | 2020-07-03 | Oligomeric nucleic acid molecule activating atoh1 gene and use thereof |
KR1020227000881A KR20220029656A (ko) | 2019-07-04 | 2020-07-03 | Atoh1 유전자를 활성화하는 올리고머 핵산 분자 및 그의 이용 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910598221 | 2019-07-04 | ||
CN201910598221.6 | 2019-07-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021000928A1 true WO2021000928A1 (zh) | 2021-01-07 |
Family
ID=74100241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/100093 WO2021000928A1 (zh) | 2019-07-04 | 2020-07-03 | 激活atoh1基因的寡聚核酸分子及其应用 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220313721A1 (zh) |
EP (1) | EP3995578A4 (zh) |
JP (1) | JP2022539770A (zh) |
KR (1) | KR20220029656A (zh) |
CN (1) | CN114174511A (zh) |
AU (1) | AU2020298647A1 (zh) |
CA (1) | CA3145567A1 (zh) |
WO (1) | WO2021000928A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117448381A (zh) * | 2023-10-26 | 2024-01-26 | 上海交通大学医学院附属第九人民医院 | 基因编辑激活Atoh1转录促进前庭毛细胞再生及修复前庭功能 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101990433A (zh) * | 2008-02-07 | 2011-03-23 | 马萨诸塞眼科耳科诊所 | 提高Atoh1表达的化合物 |
CN102947451A (zh) * | 2010-05-26 | 2013-02-27 | 库尔纳公司 | 通过抑制无调同源物1(atoh1)的天然反义转录物而治疗atoh1相关疾病 |
CN104630219A (zh) * | 2013-11-15 | 2015-05-20 | 上海交通大学医学院附属瑞金医院 | 抑癌基因IRX1的saRNA分子及其组合物和其应用 |
WO2016077689A1 (en) * | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
CN106032532A (zh) * | 2015-03-17 | 2016-10-19 | 中国医学科学院北京协和医院 | 一种小激活rna及其制备方法和应用 |
CN106480028A (zh) * | 2016-10-12 | 2017-03-08 | 上海市第七人民医院 | TPO基因的saRNA分子及其应用 |
-
2020
- 2020-07-03 CA CA3145567A patent/CA3145567A1/en active Pending
- 2020-07-03 AU AU2020298647A patent/AU2020298647A1/en active Pending
- 2020-07-03 US US17/597,281 patent/US20220313721A1/en active Pending
- 2020-07-03 EP EP20834537.1A patent/EP3995578A4/en active Pending
- 2020-07-03 CN CN202080045801.3A patent/CN114174511A/zh active Pending
- 2020-07-03 KR KR1020227000881A patent/KR20220029656A/ko unknown
- 2020-07-03 JP JP2021577888A patent/JP2022539770A/ja active Pending
- 2020-07-03 WO PCT/CN2020/100093 patent/WO2021000928A1/zh unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101990433A (zh) * | 2008-02-07 | 2011-03-23 | 马萨诸塞眼科耳科诊所 | 提高Atoh1表达的化合物 |
CN102947451A (zh) * | 2010-05-26 | 2013-02-27 | 库尔纳公司 | 通过抑制无调同源物1(atoh1)的天然反义转录物而治疗atoh1相关疾病 |
CN104630219A (zh) * | 2013-11-15 | 2015-05-20 | 上海交通大学医学院附属瑞金医院 | 抑癌基因IRX1的saRNA分子及其组合物和其应用 |
WO2016077689A1 (en) * | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
CN106032532A (zh) * | 2015-03-17 | 2016-10-19 | 中国医学科学院北京协和医院 | 一种小激活rna及其制备方法和应用 |
CN106480028A (zh) * | 2016-10-12 | 2017-03-08 | 上海市第七人民医院 | TPO基因的saRNA分子及其应用 |
Non-Patent Citations (16)
Title |
---|
ARAGAKI, M.K. TSUCHIYAR. OKAMOTOS. YOSHIOKAT. NAKAMURAN. SAKAMOTOT. KANAM. WATANABE: "Proteasomal degradation of Atohl by aberrant Wnt signaling maintains the undifferentiated state of colon cancer", BIOCHEM BIOPHYS RES COMMUN, vol. 368, 2008, pages 923 - 9, XP022511802, DOI: 10.1016/j.bbrc.2008.02.011 |
BERMINGHAM, N. A.B. A. HASSANS. D. PRICEM. A. VOLLRATHN. BEN-ARIER. A. EATOCKH. J. BELLENA. LYSAKOWSKIH. Y. ZOGHBI.: "Mathl: an essential gene for the generation of inner ear hair cells", SCIENCE, vol. 284, 1999, pages 1837 - 41 |
CHEN HONG: "The Role of Small RNA Induced INTS6 Gene Activation in Castration Resistant Prostate Cancer", CHINESE DOCTORAL DISSERTATIONS FULL-TEXT DATABASE, 1 January 2013 (2013-01-01), pages 1 - 131, XP055771442 * |
CHEN ZHONG : "Non-official translation: Research Progress of RNA Activation", JOURNAL OF CONTEMPORARY UROLOGIC AND REPRODUCTIVE ONCOLOGY, vol. 4, no. 2, 30 April 2012 (2012-04-30), pages 65 - 68, XP009525449, ISSN: 1674-4624, DOI: 10.3870/j.issn.1674-4624.2012.02.001 * |
GUBBELS, S. P., D. W. WOESSNER, J. C. MITCHELL, A. J. RICCI, J. V. BRIGANDE: "Functional auditory hair cells produced in the mammalian cochlea by in utero gene transfer", NATURE, vol. 455, 2008, pages 537 - 41, XP055258007, DOI: 10.1038/nature07265 |
GURTLER, N.A. K. LALWANI: "Etiology of syndromic and nonsyndromic sensorineural hearing loss", OTOLARYNGOL CLIN NORTH AM,, vol. 35, 2002, pages 891 - 908 |
IZUMIKAWA, M., R. MINODA, K. KAWAMOTO, K. A. ABRASHKIN, D. L. SWIDERSKI, D. F. DOLAN, D. E. BROUGH, Y.RAPHAEL: "Auditory hair cell replacement and hearing improvement by Atohl gene therapy in deaf mammals", NAT MED, vol. 11, 2005, pages 271 - 6, XP008109775, DOI: 10.1038/nm1193 |
KAWAMOTO, K.S. ISHIMOTOR. MINODAD. E. BROUGHY. RAPHAEL: "Mathl gene transfer generates new cochlear hair cells in mature guinea pigs in vivo", J NEUROSCI, vol. 23, 2003, pages 4395 - 400 |
KAZANJIAN A., SHROYER S.F.: "NOTCH Signaling and ATOH1 in Colorectal Cancers", COLORECTAL CANCER REP JUN, vol. 7, no. 2, 2011, pages 121 - 127, XP019898191, DOI: 10.1007/s11888-011-0090-5 |
LEOW, C. C.P. POLAKISW. Q. GAO: "A role for Hathl, a bHLH transcription factor, in colon adenocarcinoma", ANN N Y ACAD SCI, vol. 1059, 2005, pages 174 - 83 |
LIBERMAN, M. C.: "Quantitative assessment of inner ear pathology following ototoxic drugs or acoustic trauma", TOXICOL PATHOL, vol. 18, 1990, pages 138 - 48 |
LONG-CHENG LI , STEVEN T OKINO , HONG ZHAO , DEEPA POOKOT , ROBERT F PLACE , SHINJI URAKAMI , HIDEKI ENOKIDA , RAJIV OAHIYA: "Small dsRNAs induce transcriptional activation in human cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 103, no. 46, 14 November 2006 (2006-11-14), pages 17337 - 17342, XP002589998, ISSN: 0027-8424, DOI: 10.1073/PNAS.0607015103 * |
RICHARDSON, R. T.P. J. ATKINSON: "Atohl gene therapy in the cochlea for hair cell regeneration", EXPERT OPIN BIOL THER, vol. 15, 2015, pages 417 - 30 |
SAMBROOK ET AL.: "Molecular Cloning: Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS |
See also references of EP3995578A4 |
ZHENG, J. L.W. Q. GAO: "Overexpression of Mathl induces robust production of extra hair cells in postnatal rat inner ears", NAT NEUROSCI, vol. 3, 2000, pages 580 - 6 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117448381A (zh) * | 2023-10-26 | 2024-01-26 | 上海交通大学医学院附属第九人民医院 | 基因编辑激活Atoh1转录促进前庭毛细胞再生及修复前庭功能 |
Also Published As
Publication number | Publication date |
---|---|
US20220313721A1 (en) | 2022-10-06 |
AU2020298647A1 (en) | 2022-02-24 |
JP2022539770A (ja) | 2022-09-13 |
EP3995578A4 (en) | 2023-07-26 |
CN114174511A (zh) | 2022-03-11 |
KR20220029656A (ko) | 2022-03-08 |
EP3995578A1 (en) | 2022-05-11 |
CA3145567A1 (en) | 2021-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2990161A1 (en) | Treatment of c9ftd/als by targeting rna expanded repeat sequences | |
CN112996913B (zh) | 寡聚核酸分子及其应用 | |
WO2021000928A1 (zh) | 激活atoh1基因的寡聚核酸分子及其应用 | |
CN113260702B (zh) | 寡聚核酸分子及其在急性间歇性卟啉症治疗中的应用 | |
CN113913511A (zh) | Otulin在制备诊疗纤毛相关疾病试剂中的应用 | |
CN108130374B (zh) | 肾癌的诊断产品以及治疗药物组合物 | |
EP4289953A1 (en) | Double-stranded nucleic acid molecule for treating proliferative vitreoretinopathy and use thereof | |
WO2021249064A1 (zh) | 靶向mitf基因的核酸分子及其用途 | |
CN117343932B (zh) | 靶向抑制MS4A7基因表达的siRNA及其应用 | |
US20220096516A1 (en) | Oligonucleotide molecule and application thereof in tumor therapy | |
CA2690732A1 (en) | Rnai mediated knockdown of numa for cancer therapy | |
KR20200122183A (ko) | 암의 예방 또는 치료용 약학 조성물 | |
KR100992239B1 (ko) | Mig12 유전자의 신규한 용도 | |
CN116024211A (zh) | tRNA衍生物tRF-His-008在诊断、治疗肾癌中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20834537 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021577888 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3145567 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20227000881 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020834537 Country of ref document: EP Effective date: 20220204 |
|
ENP | Entry into the national phase |
Ref document number: 2020298647 Country of ref document: AU Date of ref document: 20200703 Kind code of ref document: A |